Skip to main content

Advertisement

Table 5 Adverse events in all patients (n = 134)

From: Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

Adverse event G0 G1 G2 G3 G4 NE All grades (%) Grade 3/4 (%)
Leucocyte 9 8 21 44 49 3 91.0 69.4
Neutrophils 9 7 17 30 67 4 90.3 72.4
Hemoglobin 27 41 38 23 2 3 77.6 18.7
Platelets 55 21 18 24 13 3 56.7 27.6
AST 87 38 3 3 0 3 32.8 2.2
ALT 82 35 9 5 0 3 36.6 3.7
Anorexia 52 59 15 2 0 6 56.7 1.5
Nausea 65 49 14 1 0 5 47.8 0.7
Vomiting 103 22 4 0 0 5 19.4 0.0
Diarrhea 112 13 2 2 0 5 12.7 1.5
Fatigue 50 59 15 6 0 4 59.7 4.5
Febrile neutropenia 120 0 0 13 0 1 9.7 9.7
Fever 97 22 12 1 0 2 26.1 0.7
Infection 118 4 5 5 1 1 11.2 4.5
Dyspnea 124 4 1 4 0 1 6.7 3.0
Interstitial pneumonia 124 4 1 4 0 1 6.7 3.0
Neuropathy 128 0 5 0 0 1 3.7 0.0
Rash 114 6 8 5 0 1 14.2 3.7
Edema 131 2 1 0 0 0 2.2 0.0
Mucositis 130 1 3 0 0 0 3.0 0.0
Allergic reaction 132 0 2 0 0 0 1.5 0.0
  1. AST aspartate transaminase, ALT alanine aminotransferase